SALKALLI- retatrutide lyophilized powder 7.5mg injection, powder, lyophilized, for solution
Guangzhou Yixin Cross-border E-commerce Co., Ltd.

Active ingredients (in each kit)

Retatrutide 7.5 mg (lyophilized powder)

Sterile Water for Injection 0.75 mL

Purpose

Antidiabetic / Weight management agent

Diluent

Uses

Helps control blood sugar in adults with type 2 diabetes (when prescribed).
Intended to assist adults with weight loss as directed by a healthcare provider.

Warnings — Read carefully and tell your doctor if any apply to you.

Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.
Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.
Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).
Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.
Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.
Pregnancy or breastfeeding: Do not use.
Children: Do not use.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.

Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.
Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

Directions — Preparation & Dosing (basic patient summary)

Concentration after reconstitution (calculation):

10 mg ÷ 1 mL = 10 mg/mL.
Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.

Typical weekly dosing schedule (example shown — follow your prescriber):

Weeks 1–4: 0.25 mL (2.5 mg) once weekly (subcutaneous)
Weeks 5–8: 0.5 mL (5 mg) once weekly
Weeks 9–12: 0.75 mL (7.5 mg) once weekly
Week 13 and onward: 1 mL (10 mg) once weekly

One carton (4 kits) provides 4 weekly doses.

How to prepare and inject (patient summary):

Wash hands with soap and water. Inspect vials for damage.
Using aseptic technique, withdraw the prescribed volume (in mL) of Sterile Water for Injection into a sterile syringe. Inject the diluent into the vial containing the lyophilized powder.
Gently swirl the vial until the powder fully dissolves. Do not shake vigorously. Solution should be clear; do not use if cloudy or particulate present.
Withdraw the prescribed volume (e.g., 0.25, 0.5, 0.75 or 1 mL) into a sterile syringe and inject subcutaneously in the abdomen, thigh, or upper arm after cleaning the site with alcohol. Rotate injection sites.
Dispose of syringe/needle in an appropriate sharps container.

Do not use

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-

administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.
Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

When using section

Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.
Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.
Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).
Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.
Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.
Pregnancy or breastfeeding: Do not use.
Children: Do not use.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.
Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

stop use

Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.
Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.
Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).
Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.
Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.
Pregnancy or breastfeeding: Do not use.
Children: Do not use.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.
Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

Keep out of reach of children.

Not for use in children.

Inactive Ingredients:

Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride, Sodium Bicarbonate.

PRINCIPAL DISPLAY PANEL

7.5mg减肥注射器-冻干款-双插盒外盒
尺寸:200 x 40 x 125 mm
工艺:350g白卡过光膜,四色印,指定位置激凸
内托:350g抽盒纸托(按外盒尺寸与产品实物大小调整尺寸槽深)



350g抽盒纸托(请供应商根据实际情况评估)
尺寸根据外盒实际尺寸而定
槽尺寸深度按包材(可按实际大小调整)



7.5mg冻干减肥注射器-内包标贴
尺寸:47x18mm
工艺:合成纸不干胶,四色印过光膜

7.5mg冻干减肥注射器-2件套封套
尺寸:200 x 127 x 81 mm
工艺:350g白卡过光膜,四色印



81mm

127mm

Salkalli

Retatrutide (lyophilized powder)

1 set containing 2 cartons (each carton contains 4 kits)

0.75ml: 7.5mg

Salkalli™ Rx USA

Retatrutide (lyophilized powder)

1 set containing 2 cartons (each carton contains 4 kits)

0.75mL: 7.5mg

For Reconstitution and Subcutaneous Use Only — Not for IV use
Rx Only — Dispense only with prescription

Each kit provides a single weekly dose.
One carton provides 4 weekly doses(4-week supply)

Each kit contains:
Retatrutide 7.5 mg vial + Sterile Water for Injection 0.75 mL vial + sterile syringe

Store at room temperature below 25 °C (77 °F) before reconstitution.
Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted.
After mixing, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours per vial.

See enclosed leaflet for full instructions.

Manufactured for:
Salkalli™
[Company address line 1]
[City, State, Country]
Customer Service: [phone] | [email] | [website]
Contents:
1 set containing 2 cartons,
each carton containing 4 complete single-use kits, each kit containing:
- 1 vial Retatrutide 7.5 mg (lyophilized powder)
- 1 vial Sterile Water for Injection 0.75 mL
- 1 sterile syringe

Storage: Store unused kits at **room temperature below 25 °C (77 °F).** Excursions between **15 °C and 30 °C (59 °F and 86 °F)** are permitted. After reconstitution, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original carton until use.

NDC: 00000-000-00. **Rx Only.** For prescription use only. Not for sale without prescription.

0.75ml: 7.5mg

DRUG FACTS — For Patient Use (Prescription)

Active ingredients (in each kit) — ***Purpose***
Retatrutide 7.5 mg (lyophilized powder) ····· Antidiabetic / Weight management agent
Sterile Water for Injection 0.75 mL ····· Diluent

Uses
- Helps control blood sugar in adults with type 2 diabetes (when prescribed).
- Intended to assist adults with weight loss as directed by a healthcare provider.

Warnings — Read carefully and tell your doctor if any apply to you.
- **Pancreatitis:** Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.
- **Allergic reaction:** Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.
- **Serious gastrointestinal disease:** May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).
- **Acute gallbladder disease:** Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.
- **Hypoglycemia warning:** Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.
- **Pregnancy or breastfeeding:** Do not use.
- **Children:** Do not use.

Drug Interactions / Precautions
- **Other antidiabetic medications:** Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
- **Drugs affecting gastrointestinal motility:** Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
- **Cardiovascular medications:** Caution with statins, digoxin, or warfarin.
  - Statins: absorption may be affected; monitor lipid levels.
  - Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.
- **General precautions:** Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects
- Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor
- If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

Directions — Preparation & Dosing (basic patient summary)

Concentration after reconstitution (calculation):
- 10 mg ÷ 1 mL = **10 mg/mL.**
- Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.

Typical weekly dosing schedule (example shown — follow your prescriber):
- Weeks 1–4: 0.25 mL (25 mg) once weekly (subcutaneous)
- Weeks 5–8: 0.5 mL (5 mg) once weekly
- Weeks 9–12: 0.75 mL (7.5 mg) once weekly
- Week 13 and onward: 1 mL (10 mg) once weekly

One carton (4 kits) provides 4 weekly doses.

How to prepare and inject (patient summary):
1. Wash hands with soap and water. Inspect vials for damage.
2. Using aseptic technique, withdraw the prescribed volume (in mL) of Sterile Water for Injection into a sterile syringe. Inject the diluent into the vial containing the lyophilized powder.
3. Gently swirl the vial until the powder fully dissolves. Do **not** shake vigorously. Solution should be clear; do not use if cloudy or particulate present.
4. Withdraw the prescribed volume (e.g., 0.25, 0.5, 0.75 or 1 mL) into a sterile syringe and inject **subcutaneously** in the abdomen, thigh, or upper arm after cleaning the site with alcohol. Rotate injection sites.
5. Dispose of syringe/needle in an appropriate sharps container.

Inactive Ingredients:
Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride, Sodium Bicarbonate.

Other information
- Store unused kits at **room temperature below 25 °C (77 °F).** Excursions between **15 °C and 30 °C (59 °F and 86 °F)** are permitted. After reconstitution, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original carton until use. Each kit is single-use. Discard any unused solution.
- Keep out of reach of children.
- For questions, contact: **Salkalli™ Customer Care:** [phone / email / website — insert]. To report side effects, call your healthcare provider.



7.5mg冻干减肥注射器-3件套封套
尺寸:200 x 127 x 122 mm
工艺:350g白卡过光膜,四色印



200mm

122mm

127mm

Salkalli™

Retatrutide
(lyophilized powder)

1 set containing 3 cartons
(each carton contains 4 kits)

0.75ml: 7.5mg

Salkalli™ ℞ USA

Retatrutide
(lyophilized powder)

1 set containing 3 cartons
(each carton contains 4 kits)

0.75mL:
7.5mg

For Reconstitution and Subcutaneous Use Only — Not for IV use
Rx Only — Dispense only with prescription

Each kit provides a single weekly dose.
One carton provides 4 weekly doses(4-week supply)

Each kit contains:
Retatrutide 7.5 mg vial + Sterile Water for Injection 0.75 mL vial + sterile syringe

Store at room temperature below 25 °C (77 °F) before reconstitution.
Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted.
After mixing, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours per vial.

See enclosed leaflet for full instructions.

Manufactured for:
Salkalli™
[Company address line 1]
[City, State, Country]
Customer Service: [phone] | [email] | [website]
Contents:
1 set containing 3 cartons,
each carton containing 4 complete single-use kits, each kit containing:
• 1 vial Retatrutide 7.5 mg (lyophilized powder)
• 1 vial Sterile Water for Injection 0.75 mL
• 1 sterile syringe

Storage: Store unused kits at **room temperature below 25 °C (77 °F).** Excursions between **15 °C and 30 °C (59 °F and 86 °F)** are permitted. After reconstitution, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original carton until use.

NDC: 00000-000-00. **Rx Only.** For prescription use only. Not for sale without prescription.

0.75ml: 7.5mg

DRUG FACTS — For Patient Use (Prescription)

Active ingredients (in each kit)	***Purpose***
Retatrutide 7.5 mg (lyophilized powder)	Antidiabetic / Weight management agent
Sterile Water for Injection 0.75 mL	Diluent

Uses
• Helps control blood sugar in adults with type 2 diabetes (when prescribed).
• Intended to assist adults with weight loss as directed by a healthcare provider.

Warnings — Read carefully and tell your doctor if any apply to you.
• **Pancreatitis:** Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.
• **Allergic reaction:** Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.
• **Serious gastrointestinal disease:** May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).
• **Acute gallbladder disease:** Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.
• **Hypoglycemia warning:** Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.
• **Pregnancy or breastfeeding:** Do not use.
• **Children:** Do not use.

Drug Interactions / Precautions
• **Other antidiabetic medications:** Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
• **Drugs affecting gastrointestinal motility:** Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
• **Cardiovascular medications:** Caution with statins, digoxin, or warfarin.
  ○ Statins: absorption may be affected; monitor lipid levels.
  ○ Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.
• **General precautions:** Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects
• Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor
• If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

Directions — Preparation & Dosing (basic patient summary)

Concentration after reconstitution (calculation):
• 10 mg ÷ 1 mL = 10 mg/mL.
• Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.

Typical weekly dosing schedule (example shown — follow your prescriber):
• Weeks 1–4: 0.25 mL (25 mg) once weekly (subcutaneous)
• Weeks 5–8: 0.5 mL (5 mg) once weekly
• Weeks 9–12: 0.75 mL (7.5 mg) once weekly
• Week 13 and onward: 1 mL (10 mg) once weekly
One carton (4 kits) provides 4 weekly doses.

How to prepare and inject (patient summary):
1. Wash hands with soap and water. Inspect vials for damage.
2. Using aseptic technique, withdraw the prescribed volume (in mL) of Sterile Water for Injection into a sterile syringe. Inject the diluent into the vial containing the lyophilized powder.
3. Gently swirl the vial until the powder fully dissolves. Do **not** shake vigorously. Solution should be clear; do not use if cloudy or particulate present.
4. Withdraw the prescribed volume (e.g., 0.25, 0.5, 0.75 or 1 mL) into a sterile syringe and inject **subcutaneously** in the abdomen, thigh, or upper arm after cleaning the site with alcohol. Rotate injection sites.
5. Dispose of syringe/needle in an appropriate sharps container.

Inactive Ingredients:
Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride, Sodium Bicarbonate.

Other information
• Store unused kits at **room temperature below 25 °C (77 °F).** Excursions between **15 °C and 30 °C (59 °F and 86 °F)** are permitted. After reconstitution, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original carton until use. Each kit is single-use. Discard any unused solution.
• Keep out of reach of children.
• For questions, contact: **Salkalli™ Customer Care:** [phone / email / website — insert]. To report side effects, call your healthcare provider.

7.5mg冻干减肥注射器-4件套封套
尺寸:200 x 127 x 162 mm
工艺:350g白卡过光膜,四色印

根据盒子调合适封套



200mm

162mm

Salkalli™

Retatrutide (lyophilized powder)

1 set containing 4 cartons (each carton contains 4 kits)

0.75ml: 7.5mg

127mm

Salkalli™ ℞ USA

Retatrutide (lyophilized powder)

1 set containing 4 cartons (each carton contains 4 kits)

0.75mL: 7.5mg

For Reconstitution and Subcutaneous Use Only — Not for IV use
Rx Only — Dispense only with prescription

Each kit provides a single weekly dose.
One carton provides 4 weekly doses(4-week supply)

Each kit contains:
Retatrutide 7.5 mg vial + Sterile Water for Injection 0.75 mL vial + sterile syringe

Store at room temperature below 25 °C (77 °F) before reconstitution.
Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted.
After mixing, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours per vial.

See enclosed leaflet for full instructions.

Manufactured for:
Salkalli™
[Company address line 1]
[City, State, Country]
Customer Service: [phone] | [email] | [website]
Contents:
1 set containing 4 cartons,
each carton containing 4 complete single-use kits, each kit containing:
- 1 vial Retatrutide 7.5 mg (lyophilized powder)
- 1 vial Sterile Water for Injection 0.75 mL
- 1 sterile syringe

Storage: Store unused kits at **room temperature below 25 °C (77 °F).** Excursions between **15 °C and 30 °C (59 °F and 86 °F)** are permitted. After reconstitution, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original carton until use.

NDC: 00000-000-00. **Rx Only.** For prescription use only. Not for sale without prescription.

0.75ml: 7.5mg



DRUG FACTS — For Patient Use (Prescription)

Active ingredients (in each kit) — ***Purpose***
Retatrutide 7.5 mg (lyophilized powder) ····· Antidiabetic / Weight management agent
Sterile Water for Injection 0.75 mL ····· Diluent

Uses
- Helps control blood sugar in adults with type 2 diabetes (when prescribed).
- Intended to assist adults with weight loss as directed by a healthcare provider.

Warnings — Read carefully and tell your doctor if any apply to you.
- **Pancreatitis:** Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.
- **Allergic reaction:** Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.
- **Serious gastrointestinal disease:** May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).
- **Acute gallbladder disease:** Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.
- **Hypoglycemia warning:** Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.
- **Pregnancy or breastfeeding:** Do not use.
- **Children:** Do not use.

Drug Interactions / Precautions
- **Other antidiabetic medications:** Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.
- **Drugs affecting gastrointestinal motility:** Retatrutide may delay gastric emptying. Co-administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.
- **Cardiovascular medications:** Caution with statins, digoxin, or warfarin.
  - Statins: absorption may be affected; monitor lipid levels.
  - Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.
- **General precautions:** Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects
- Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor
- If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

Directions — Preparation & Dosing (basic patient summary)

Concentration after reconstitution (calculation):
- 10 mg ÷ 1 mL = **10 mg/mL**
- Therefore: **0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.**

Typical weekly dosing schedule (example shown — follow your prescriber):
- Weeks 1–4: 0.25 mL (25 mg) once weekly (subcutaneous)
- Weeks 5–8: 0.5 mL (5 mg) once weekly
- Weeks 9–12: 0.75 mL (7.5 mg) once weekly
- Week 13 and onward: 1 mL (10 mg) once weekly

One carton (4 kits) provides 4 weekly doses.

How to prepare and inject (patient summary):
1. Wash hands with soap and water. Inspect vials for damage.
2. Using aseptic technique, withdraw the prescribed volume (in mL) of Sterile Water for Injection into a sterile syringe. Inject the diluent into the vial containing the lyophilized powder.
3. Gently swirl the vial until the powder fully dissolves. Do **not** shake vigorously. Solution should be clear; do not use if cloudy or particulate present.
4. Withdraw the prescribed volume (e.g., 0.25, 0.5, 0.75 or 1 mL) into a sterile syringe and inject **subcutaneously** in the abdomen, thigh, or upper arm after cleaning the site with alcohol. Rotate injection sites.
5. Dispose of syringe/needle in an appropriate sharps container.

Inactive Ingredients:
Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride, Sodium Bicarbonate.

Other information
- Store unused kits at **room temperature below 25 °C (77 °F)**. Excursions between **15 °C and 30 °C (59 °F and 86 °F)** are permitted. After reconstitution, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original carton until use. Each kit is single-use. Discard any unused solution.
- Keep out of reach of children.
- For questions, contact: **Salkalli™ Customer Care**: [phone / email / website — insert]. To report side effects, call your healthcare provider.

SALKALLI

retatrutide lyophilized powder 7.5mg injection, powder, lyophilized, for solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	**Item Code (Source)**	NDC:84778-114
Route of Administration	SUBCUTANEOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
RETATRUTIDE (UNII: NOP2Y096GV) (RETATRUTIDE - UNII:NOP2Y096GV)	RETATRUTIDE	7.5 mg in 0.75 mL

Inactive Ingredients

Ingredient Name	Strength
SODIUM BICARBONATE (UNII: 8MDF5V39QO)	
MANNITOL (UNII: 3OWL53L36A)	
SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM (UNII: 3980JIH2SW)	
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)	

SODIUM CHLORIDE (UNII: 451W47IQ8X)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:84778-114-02	2 in 1 PACKAGE, COMBINATION	10/30/2025	
1		4 in 1 CARTON		
1		0.75 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		
2	NDC:84778-114-01	4 in 1 CARTON	10/30/2025	
2		0.75 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		
3	NDC:84778-114-03	3 in 1 PACKAGE, COMBINATION	10/30/2025	
3		4 in 1 CARTON		
3		0.75 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		
4	NDC:84778-114-04	4 in 1 PACKAGE, COMBINATION	10/30/2025	
4		4 in 1 CARTON		
4		0.75 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Export only		10/30/2025	

Labeler - Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881)

Registrant - Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881)

Establishment

Name	Address	ID/FEI	Business Operations
Guangzhou Yixin Cross-border E-commerce Co., Ltd.		455800881	label(84778-114) , manufacture(84778-114)

Revised: 11/2025 Guangzhou Yixin Cross-border E-commerce Co., Ltd.